Psy Therapeutics is discovering / developing unique therapies to improve lives of those affected by neuropsychiatric and neurodegenerative disorders. The firm's pipeline of novel small molecules applies innovative platform technologies ttargets supported by clinical and preclinical science. This risk-contained approach has led to the discovery of highly brain penetrant and well-tolerated molecules that overcome the limitations of existing treatments. Psys mission-focused progress is driven by our team of accomplished biopharma executives, renowned clinicians, and neuroscience experts deeply committed to advancing mental and neurological health
